These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26240264)

  • 1. Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP as a Target to Lower CVD Risk: Suspension of Disbelief?
    Hovingh GK; Ray KK; Boekholdt SM
    Circulation; 2015 Aug; 132(5):433-40. PubMed ID: 26240264
    [No Abstract]   [Full Text] [Related]  

  • 2. Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case.
    Barter PJ; Nicholls SJ; Kastelein JJ; Rye KA
    Circulation; 2015 Aug; 132(5):423-32. PubMed ID: 26240263
    [No Abstract]   [Full Text] [Related]  

  • 3. Future of cholesteryl ester transfer protein inhibitors.
    Rader DJ; deGoma EM
    Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
    Barter P; Rye KA
    Trends Pharmacol Sci; 2011 Dec; 32(12):694-9. PubMed ID: 22088767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease.
    Schmidt AF; Hunt NB; Gordillo-Marañón M; Charoen P; Drenos F; Kivimaki M; Lawlor DA; Giambartolomei C; Papacosta O; Chaturvedi N; Bis JC; O'Donnell CJ; Wannamethee G; Wong A; Price JF; Hughes AD; Gaunt TR; Franceschini N; Mook-Kanamori DO; Zwierzyna M; Sofat R; Hingorani AD; Finan C
    Nat Commun; 2021 Sep; 12(1):5640. PubMed ID: 34561430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk.
    Mantlo NB; Escribano A
    J Med Chem; 2014 Jan; 57(1):1-17. PubMed ID: 23941686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [HDL and CETP in atherogenesis].
    Pöss J; Böhm M; Laufs U
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The controversy over the use of cholesteryl ester transfer protein inhibitors: is there some light at the end of the tunnel?
    Quintão EC
    Eur J Clin Invest; 2016 Jun; 46(6):581-9. PubMed ID: 26992444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction.
    Gutstein DE; Krishna R; Johns D; Surks HK; Dansky HM; Shah S; Mitchel YB; Arena J; Wagner JA
    Clin Pharmacol Ther; 2012 Jan; 91(1):109-22. PubMed ID: 22130116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.
    Goldberg AS; Hegele RA
    Drug Des Devel Ther; 2012; 6():251-9. PubMed ID: 23055695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.
    Landmesser U; von Eckardstein A; Kastelein J; Deanfield J; Lüscher TF
    Eur Heart J; 2012 Jul; 33(14):1712-5. PubMed ID: 22696435
    [No Abstract]   [Full Text] [Related]  

  • 12. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
    Niesor EJ
    Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspective. The failure of cholesteryl ester transfer protein inhibitors: is it due to increased blood viscosity?
    Sloop GD; Weidman JJ; St Cyr JA
    Ther Adv Cardiovasc Dis; 2015 Apr; 9(2):32-5. PubMed ID: 25573766
    [No Abstract]   [Full Text] [Related]  

  • 14. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
    Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
    Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesteryl ester transfer protein inhibitors: challenges and perspectives.
    Filippatos TD; Klouras E; Barkas F; Elisaf M
    Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):953-62. PubMed ID: 27171534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The end of the road for CETP inhibitors after torcetrapib?
    Joy T; Hegele RA
    Curr Opin Cardiol; 2009 Jul; 24(4):364-71. PubMed ID: 19522058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors.
    Miyares MA
    Ann Pharmacother; 2011 Jan; 45(1):84-94. PubMed ID: 21205945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on CETP inhibition.
    Davidson MH
    J Clin Lipidol; 2010; 4(5):394-8. PubMed ID: 21122682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CETP Inhibition in CVD Prevention: an Actual Appraisal.
    Di Bartolo B; Takata K; Duong M; Nicholls SJ
    Curr Cardiol Rep; 2016 May; 18(5):43. PubMed ID: 27002619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?
    Schaefer EJ
    Curr Opin Lipidol; 2013 Jun; 24(3):259-64. PubMed ID: 23652567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.